-
03:25:31 AM

ABBV Stock News

05/31/23 2:30 AM
NYSE : ABBV
clinical trial
Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus
-At week 24, upadacitinib 30 mg given alone or as a combination therapy met the primary endpoint of systemic lupus erythematosus Responder Index and steroid dose less than or equal to 10 mg prednisone equivalent once per day in patients with moderately to severely active SLE receiving standard lupus therapies 1- Upadacitinib maintained greater...
RHEA-AI
negative
05/25/23 8:45 AM
NYSE : ABBV
clinical trial
New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease
AbbVie today announced the New England Journal of Medicine published results from the pivotal Phase 3 clinical trials– U-EXCEL, U-EXCEED and U-ENDURE– evaluating upadacitinib in adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant...
RHEA-AI
negative
05/24/23 9:00 AM
NYSE : ABBV
AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ® (upadacitinib) Across Multiple Rheumatic Diseases at the EULAR 2023 Congress
-Five-year results from SELECT-COMPARE evaluating the efficacy and safety of RINVOQ ® and HUMIRA ®, both in combination with methotrexate, are reported for adult patients with moderate to severely active rheumatoid arthritis who had an inadequate response to MTX 1. -Three-year results from SELECT-PsA 1 evaluating the efficacy and safety of RINVOQ are...
RHEA-AI
very negative
05/19/23 12:38 PM
Nasdaq, NYSE : GMAB, ABBV
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Genmab A/S today announced that the U.S. Food and Drug Administration has approved EPKINLY™ as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B‑ cell lymphoma, after...
RHEA-AI
neutral
05/19/23 12:34 PM
NYSE : ABBV
EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
AbbVie today announced that the U.S. Food and Drug Administration has approved EPKINLY TM, as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, including DLBCL arising from indolent...
RHEA-AI
neutral
05/18/23 12:25 PM
NYSE : ABBV
fda approval
U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults
–The co-primary endpoints of endoscopic response and clinical remission were achieved by significantly more patients treated with RINVOQ at week 12 and week 52 versus placebo 1– Clinical response was achieved by significantly more patients treated with RINVOQ versus placebo as early as week 2 in induction studies 1– This indication marks the seventh FDA...
RHEA-AI
neutral